Bone metastasis: histological changes and pathophysiological mechanisms in osteolytic or osteosclerotic localizations. A review
- PMID: 21620753
- DOI: 10.1016/j.morpho.2011.02.004
Bone metastasis: histological changes and pathophysiological mechanisms in osteolytic or osteosclerotic localizations. A review
Abstract
The development of a bone metastasis involves interactions between the tumor cells, the bone marrow microenvironment and the bone cells themselves. A better understanding of the pathophysiological changes occurring in bone metastasis can be obtained from histopathological examination of invaded specimens. This review focuses on the main molecular mechanisms implied in the localization and growth of malignant cells in the bone marrow. The corresponding histologic developmental stages are illustrated both in osteolytic (or mixed metastasis) or in the osteosclerotic forms by histological analysis, immunohistochemistry and microcomputed tomographic analysis of bone samples. In both cases, the malignant cells find a "fertile soil" in the bone marrow microenvironment. They use the growth factors released by bone cells for the coupling between osteoclasts/osteoblasts to promote their own development. In turn, they elaborate a variety of cytokines that can promote osteoclastogenesis (PTHrP, IL-1, IL-6…) or on the contrary, other growth factors that can boost the osteoblastic activity (ET1, IGFs). A "vicious circle" occurs between the malignant cells and the bone cells leading to the radiological expression of the metastasis.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.
Similar articles
-
[Pathophysiology of bone metastases].Prog Urol. 2003 Apr;13(2 Suppl 1):9-17. Prog Urol. 2003. PMID: 12815804 Review. French.
-
Mechanisms of bone metastasis.N Engl J Med. 2004 Apr 15;350(16):1655-64. doi: 10.1056/NEJMra030831. N Engl J Med. 2004. PMID: 15084698 Review. No abstract available.
-
Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6285s-6290s. doi: 10.1158/1078-0432.CCR-06-0813. Clin Cancer Res. 2006. PMID: 17062715 Review.
-
RANK ligand is a prerequisite for cancer-associated osteolytic lesions.J Pathol. 2002 Oct;198(2):228-36. doi: 10.1002/path.1199. J Pathol. 2002. PMID: 12237883
-
Role of Wnts in prostate cancer bone metastases.J Cell Biochem. 2006 Mar 1;97(4):661-72. doi: 10.1002/jcb.20735. J Cell Biochem. 2006. PMID: 16447163 Review.
Cited by
-
Characterization of neuroblastoma bone invasion/metastasis in established bone metastatic model of SY5Y and KCNR cell lines.Childs Nerv Syst. 2013 Jul;29(7):1097-105. doi: 10.1007/s00381-013-2086-8. Epub 2013 Apr 5. Childs Nerv Syst. 2013. PMID: 23559392
-
Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2.Int J Mol Sci. 2020 Sep 14;21(18):6723. doi: 10.3390/ijms21186723. Int J Mol Sci. 2020. PMID: 32937821 Free PMC article. Review.
-
Walker 256/B malignant breast cancer cells improve femur angioarchitecture and disrupt hematological parameters in a rat model of tumor osteolysis.Tumour Biol. 2014 Apr;35(4):3663-70. doi: 10.1007/s13277-013-1485-5. Epub 2013 Dec 8. Tumour Biol. 2014. PMID: 24318993
-
Radionuclide Treatment with 153Sm-EDTMP is Effective for the Palliation of Bone Pain in the Context of Extensive Bone Marrow Metastases: A Case Report.Asia Ocean J Nucl Med Biol. 2014 Fall;2(2):131-4. Asia Ocean J Nucl Med Biol. 2014. PMID: 27408870 Free PMC article.
-
Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials.Front Oncol. 2023 Feb 13;13:1133828. doi: 10.3389/fonc.2023.1133828. eCollection 2023. Front Oncol. 2023. PMID: 36860316 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials